A total of 79 patients (98 eyes) received anti-VEGF therapy for neovascular ARMD at our institution from January 2018 to December 2021, of whom 72 patients (87 eyes) met the inclusion criteria and were included in this study. The gene discussed is VEGFA; the disease is age-related macular degeneration.